TWI558703B - 三唑并吡啶 - Google Patents

三唑并吡啶 Download PDF

Info

Publication number
TWI558703B
TWI558703B TW101114259A TW101114259A TWI558703B TW I558703 B TWI558703 B TW I558703B TW 101114259 A TW101114259 A TW 101114259A TW 101114259 A TW101114259 A TW 101114259A TW I558703 B TWI558703 B TW I558703B
Authority
TW
Taiwan
Prior art keywords
amino
phenyl
triazolo
pyridin
alkyl
Prior art date
Application number
TW101114259A
Other languages
English (en)
Chinese (zh)
Other versions
TW201245194A (en
Inventor
渥克 史古茲
德克 科斯蒙德
安特杰 瑪格利特 文格納
傑爾哈德 希梅斯特
德特勒夫 施焦度
飛利浦 里恩那
哈特莫特 史區洛克
漢斯 布里安
Original Assignee
拜耳知識產權公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 拜耳知識產權公司 filed Critical 拜耳知識產權公司
Publication of TW201245194A publication Critical patent/TW201245194A/zh
Application granted granted Critical
Publication of TWI558703B publication Critical patent/TWI558703B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW101114259A 2011-04-21 2012-04-20 三唑并吡啶 TWI558703B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11163342 2011-04-21
EP11167872 2011-05-27

Publications (2)

Publication Number Publication Date
TW201245194A TW201245194A (en) 2012-11-16
TWI558703B true TWI558703B (zh) 2016-11-21

Family

ID=46124297

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101114259A TWI558703B (zh) 2011-04-21 2012-04-20 三唑并吡啶

Country Status (39)

Country Link
US (1) US20140120087A1 (https=)
EP (1) EP2699575B1 (https=)
JP (1) JP5989091B2 (https=)
KR (1) KR20140025470A (https=)
CN (1) CN103608350B (https=)
AP (1) AP3491A (https=)
AR (1) AR086191A1 (https=)
AU (1) AU2012244859B2 (https=)
CA (1) CA2833657A1 (https=)
CL (1) CL2013003044A1 (https=)
CO (1) CO6801751A2 (https=)
CR (1) CR20130539A (https=)
CY (1) CY1116439T1 (https=)
DK (1) DK2699575T3 (https=)
DO (1) DOP2013000244A (https=)
EA (1) EA023766B1 (https=)
EC (1) ECSP13013011A (https=)
ES (1) ES2539265T3 (https=)
GT (1) GT201300254A (https=)
HR (1) HRP20150517T1 (https=)
HU (1) HUE025496T2 (https=)
IL (1) IL228704A0 (https=)
JO (1) JO3040B1 (https=)
MA (1) MA35049B1 (https=)
ME (1) ME02143B (https=)
MX (1) MX348783B (https=)
MY (1) MY164939A (https=)
PE (1) PE20141351A1 (https=)
PH (1) PH12013502169A1 (https=)
PL (1) PL2699575T3 (https=)
PT (1) PT2699575E (https=)
RS (1) RS54044B1 (https=)
SA (1) SA112330466B1 (https=)
SG (1) SG194003A1 (https=)
SI (1) SI2699575T1 (https=)
TW (1) TWI558703B (https=)
UY (1) UY34034A (https=)
WO (1) WO2012143329A1 (https=)
ZA (1) ZA201308707B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013027096A2 (pt) 2011-04-21 2016-12-27 Gilead Sciences Inc compostos de benzotiazol e seu uso farmacêutico
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
WO2013103724A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids
CN104284896B (zh) 2012-03-14 2016-06-01 拜耳知识产权有限责任公司 取代的咪唑并哒嗪
CA2878481A1 (en) 2012-07-10 2014-01-16 Bayer Pharma Aktiengesellschaft Method for preparing substituted triazolopyridines
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014195274A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines
JP2016527193A (ja) * 2013-06-07 2016-09-08 バイエル・ファルマ・アクティエンゲゼルシャフト 置換トリアゾロピリジン
SG11201509351UA (en) * 2013-06-10 2015-12-30 Bayer Pharma AG Novel compounds for the treatment of cancer
HK1219879A1 (zh) * 2013-06-11 2017-04-21 Bayer Pharma Aktiengesellschaft 用於治疗癌症的包含mps-1激酶抑制剂和有丝分裂抑制剂的组合
RS56034B1 (sr) * 2013-06-11 2017-09-29 Bayer Pharma AG Derivati prolekova supstituisanih triazolopiridina
EP2860177A3 (en) 2013-09-20 2015-06-10 Bayer Intellectual Property GmbH Synthesis of functionalized arenes
FI3283642T3 (fi) 2015-04-17 2024-01-11 Crossfire Oncology Holding B V Prognostisia biomarkkereita ttk-inhibiittorikemoterapiaan
CN109963854B (zh) * 2017-03-16 2022-04-12 江苏恒瑞医药股份有限公司 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
NZ780966A (en) 2019-04-18 2026-02-27 Univ Johns Hopkins Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a] pyridine derivatives and use thereof
JP2022539208A (ja) 2019-07-03 2022-09-07 スミトモ ファーマ オンコロジー, インコーポレイテッド チロシンキナーゼ非受容体1(tnk1)阻害剤およびその使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008025821A1 (en) * 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
MX2007001943A (es) 2004-08-17 2007-05-09 Galderma Res & Dev Nuevos compuestos biaromaticos activadores de los receptores del tipo receptor activado del proliferador de peroxisoma (ppar) y su uso en composiciones cosmeticas o farmaceuticas.
US8053574B2 (en) 2007-07-18 2011-11-08 Novartis Ag Organic compounds
MX2010002115A (es) 2007-08-23 2010-06-01 Aztrazeneca Ab 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos.
CA2691448A1 (en) * 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
MX2010005700A (es) * 2007-11-27 2010-06-11 Cellzome Ltd Amino triazoles como inhibidores pi3k.
SG173610A1 (en) 2009-02-13 2011-09-29 Fovea Pharmaceuticals Sa [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors
CN102413831B (zh) 2009-04-29 2014-06-04 拜耳知识产权有限责任公司 取代的咪唑并喹喔啉
CA2772790C (en) 2009-09-04 2017-06-27 Benjamin Bader Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008025821A1 (en) * 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors

Also Published As

Publication number Publication date
AU2012244859A1 (en) 2013-10-31
EA023766B1 (ru) 2016-07-29
AU2012244859B2 (en) 2017-06-08
IL228704A0 (en) 2013-12-31
TW201245194A (en) 2012-11-16
AR086191A1 (es) 2013-11-27
HUE025496T2 (en) 2016-04-28
HK1190398A1 (zh) 2014-07-04
EP2699575B1 (en) 2015-03-25
DK2699575T3 (da) 2015-06-22
CO6801751A2 (es) 2013-11-29
CA2833657A1 (en) 2012-10-26
JP2014511887A (ja) 2014-05-19
ES2539265T3 (es) 2015-06-29
SI2699575T1 (sl) 2015-10-30
PT2699575E (pt) 2015-07-29
JP5989091B2 (ja) 2016-09-07
NZ616456A (en) 2015-09-25
MY164939A (en) 2018-02-15
EA201301181A1 (ru) 2014-08-29
WO2012143329A1 (en) 2012-10-26
MX348783B (es) 2017-06-28
ME02143B (me) 2015-10-20
SG194003A1 (en) 2013-11-29
ECSP13013011A (es) 2013-12-31
RS54044B1 (sr) 2015-10-30
AP2013007182A0 (en) 2013-10-31
AP3491A (en) 2015-12-31
CN103608350A (zh) 2014-02-26
GT201300254A (es) 2015-09-01
EP2699575A1 (en) 2014-02-26
CR20130539A (es) 2013-12-04
HRP20150517T1 (hr) 2015-06-19
US20140120087A1 (en) 2014-05-01
KR20140025470A (ko) 2014-03-04
PE20141351A1 (es) 2014-11-01
DOP2013000244A (es) 2014-03-16
ZA201308707B (en) 2016-07-27
SA112330466B1 (ar) 2015-09-28
CN103608350B (zh) 2015-11-25
CL2013003044A1 (es) 2014-05-02
MA35049B1 (fr) 2014-04-03
JO3040B1 (ar) 2016-09-05
PH12013502169A1 (en) 2014-01-13
CY1116439T1 (el) 2017-02-08
PL2699575T3 (pl) 2015-08-31
MX2013012289A (es) 2013-11-21
UY34034A (es) 2012-11-30

Similar Documents

Publication Publication Date Title
TWI558703B (zh) 三唑并吡啶
EP2507235B1 (en) Triazolopyrimidines
EP2507236B1 (en) Triazolopyridine derivates
EP2507233B1 (en) Substituted triazolopyridines
JP5841078B2 (ja) イミダゾピラジン
CA2802629A1 (en) Substituted triazolopyridines
WO2012160029A1 (en) Substituted triazolopyridines

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees